Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202216910 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Giulio Donati und 12 weiteren Autor:innen. Beteiligte Einrichtung: European Institute of Oncology (IEO) - IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Lymphoma, Lymphoma, B-Cell. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS, Fondazione Regionale per la Ricerca Biomedica, Fondazione Umberto Veronesi.
Abstract (Originalsprache)
MYC is a key oncogenic driver in multiple tumor types, but concomitantly endows cancer cells with a series of vulnerabilities that provide opportunities for targeted pharmacological intervention. For example, drugs that suppress mitochondrial respiration selectively kill MYC‐overexpressing cells. Here, we unravel the mechanistic basis for this synthetic lethal interaction and exploit it to improve the anticancer effects of the respiratory complex I inhibitor IACS‐010759. In a B‐lymphoid cell line, ectopic MYC activity and treatment with IACS‐010759 added up to induce oxidative stress, with consequent depletion of reduced glutathione and lethal disruption of redox homeostasis. This effect could be enhanced either with inhibitors of NADPH production through the pentose phosphate pathway, or with ascorbate (vitamin C), known to act as a pro‐oxidant at high doses. In these conditions, ascorbate synergized with IACS‐010759 to kill MYC‐overexpressing cells in vitro and reinforced its therapeutic action against human B‐cell lymphoma xenografts. Hence, complex I inhibition and high‐dose ascorbate might improve the outcome of patients affected by high‐grade lymphomas and potentially other MYC‐driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- European Institute of Oncology (IEO) - IRCCS, Milan, Italy.
- Center for Genomic Science of IIT@SEMM, Milan, Italy.
- DiSFeB, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
- IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Dipartimento di Biotecnologie e Scienze della Vita, Università dell'Insubria, Varese, Italy.
ORCID-Profile: Giulio Donati, Alessandro Verrecchia, Veronica Vallelonga, Matteo Audano, Laura Cassina, Giorgio Binelli, Bruno Amati
Förderung
- Fondazione AIRC per la ricerca sul cancro ETS
- Fondazione Regionale per la Ricerca Biomedica
- Fondazione Umberto Veronesi
- Ministero della Salute
Zitieren
APA
Donati, G., Nicoli, P., Verrecchia, A., Vallelonga, V., Croci, O., Rodighiero, S., Audano, M., Cassina, L., Ghsein, A., Binelli, G., Boletta, A., Mitro, N., & Amati, B. (2023). Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216910
Vancouver
Donati G, Nicoli P, Verrecchia A, Vallelonga V, Croci O, Rodighiero S, et al. Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202216910
BibTeX
@article{Donati2023,
author = {Donati, Giulio and Nicoli, Paola and Verrecchia, Alessandro and Vallelonga, Veronica and Croci, Ottavio and Rodighiero, Simona and Audano, Matteo and Cassina, Laura and Ghsein, Aya and Binelli, Giorgio and Boletta, Alessandra and Mitro, Nico and Amati, Bruno},
title = {Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202216910}
}
EUVIMED